Sodium azulensulfonate- Sichuan Guokang Pharmaceutical
Latest Information Update: 02 May 2016
At a glance
- Originator Sichuan Guokang Pharmaceutical
- Mechanism of Action Inflammation mediator modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Gastritis